-
Huafon Group acquires DuPont bio-based PDO+PTT business for US$240 million
Time of Update: 2022-10-24
. This time Huafon Group acquired the assets of DuPont's bio-based business, mainly including its two production bases in the United States, one is a DuPont joint venture production base in Tennessee, which owns two world-renowned brands, Susterra® and Zemea® , The main business is the research and development, production and sales of bio-based PDO (1,3-propanediol) that can produce high-performance polyester plastics with biodegradable properties that are easy to circulate naturally .
-
Bertsie Lecture Hall: Chemiluminescent Inter-Aperture Interference Solutions
Time of Update: 2022-09-14
Hong Kong Beijing Shanghai Guangzhou Chengdu Jinan Welcome to pay attention to The official WeChat of Birch (WeChat public account: Bio-Gene)
-
Directly hit the fermentation exhibition, the star product of Xinlai - sterile diaphragm valve
Time of Update: 2022-08-15
The static sealing diaphragm valve has no wear and tear on its sealing components, and the valve structure has no dead angle, so it is more hygienic and durable From July 14th to 16th, Kinglai Group will make a heavy appearance at the 2022 BIO 9th International Bio-Fermentation Exhibition Product and Technology Equipment Exhibition!
-
Express aims to functionally cure hepatitis B, and the first dose of a new immunotherapy phase 2 trial has been completed
Time of Update: 2022-01-26
▎WuXi AppTec Content Team Editor A few days ago, VBI Vaccines announced that the second phase 2a/2b clinical trial of VBI-2601 (BRII-179), a novel recombinant protein immunotherapy jointly developed with Brii Biosciences, has been completed.
-
The world's first international clinical trial (Phase III) of the new crown inactivated vaccine officially launched
Time of Update: 2020-07-19
On June 23, the launch ceremony of China Pharmaceutical Group China Bionew Crown Inactivated Vaccine (Phase III) United Arab Emirates was held simultaneously by video conference in Beijing, Wuhan, And
-
Concentric retrograde, Sanno Bio Million Sage Medicines To Help Wuhan First Line
Time of Update: 2020-05-31
Figure 1: SanNo Sansan anti-new coronavirus pneumonia drug donation ceremony February 14, the National Health and Health Commission and the State Administration of Traditional Chinese Medicine jointl
-
Roche's $450 million acquisition of iquum to enter the market of molecular diagnosis POC
Time of Update: 2014-04-08
Source: Bio Valley April 7, 2014 / Bio Valley bio on April 7, 2014 Iqum, located in Massachusetts, USA, focuses on the development of point of care (POC) products for the molecular diagnosis market In
